Curanex Pharmaceuticals Faces Nasdaq Delisting Warning
I'm PortAI, I can summarize articles.
Curanex Pharmaceuticals Inc. (CURX) has received a warning from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company has until May 4, 2026, to address this issue, with a possible 180-day extension. Non-compliance may lead to delisting from the Nasdaq Capital Market. Curanex is a Nevada-based pharmaceutical company focused on developing pharmaceutical products.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments